Protect patients from surprise medical billing and reduce payments to some health care providers working in facilities where surprise bills are likely
Allow some generic or biosimilar drugs to enter the market earlier, on average, than under current law
Impose new rules for insurers’ contracts with pharmacy benefit managers and health care providers
Extend funding for community health centers and certain other federal health care programs
Increase access to health, cost, and quality information among patients, providers, and insurers, which would create new administrative responsibilities that increase costs for insurers and pharmacy benefit managers
Impose intergovernmental and private-sector mandates by prohibiting certain medical billing practices, limiting other commercial activities, and prohibiting the sale of tobacco products to anyone under the age of 21, among many other duties
Estimated budgetary effects would primarily stem from
Reduced federal subsidies for health care and health insurance
Increased direct spending for community health centers and other federal health programs
Areas of significant uncertainty include
Accurately anticipating the nature and effects of provider and insurer responses to the bill’s provisions
Accurately projecting how federal and state agencies would implement the law
Estimating quantities, sales, and market effects of introductions of new pharmaceutical products
Determining how increased transparency would affect prices and private insurance premiums
